Vaccination against infectious diseases: What is promising?

Berger, Annemarie

doi:10.1007/s00430-014-0346-1

Cited by 12 publications

(7 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides vaccination [57] further iatrogenic actions helping to survive diseased people with impaired immunity would be the successful treatment of sleeping sickness followed by reduction of spread of Trypanosoma brucei , or similarly treatment of plague, cholera, malaria, etc. Absence of those infectious agents that kill patients with severe immunodeficiency would have contributed to preserve the life of HIV-1 infected subjects with minor immunodeficiency and thus allowing the spread of HIV by the sexual route.…”

Section: Further Possible Reasons Favoring Hiv Spread Some Decades Agomentioning

confidence: 99%

Aspects on the history of transmission and favor of distribution of viruses by iatrogenic action: perhaps an example of a paradigm of the worldwide spread of HIV

Gürtler

Eberle

2017

Med Microbiol Immunol

View full text Add to dashboard Cite

Transmission of infectious agents might be associated with iatrogenic actions of charitable help in health care. An example is the vaccination against yellow fever in USA that transmitted hepatitis B virus. Another example is injections of praziquantel for treatment and cure of schistosomiasis in Central and Northern Africa, with a focus in Egypt that has spread hepatitis C virus. There is no indication that human T-lymphotropic virus type 1 was spread by injection treatment for African trypanosomiasis, syphilis and treponematosis, but these treatments might have contributed to the early spread of human immunodeficiency virus type 1 (HIV-1) in Central Africa. Slave trade contributed as well to the spread of viruses from Africa to the Americas; it was stopped in 1850. Until that date HIV-1 was not transported to the Americas. By analysis of nucleic acid sequence data it can be concluded that the continental spread of HCV and HIV-1 might have started around 1920 with an exponential phase from 1940 to 1970. Further iatrogenic actions that promoted the spread of HCV and HIV-1 might be vaccinations to prevent deadly diseases. The successful vaccination was followed by diminution of the infectious agent in the population such as small pox, yellow fever and measles. Measurements to reduce the spread of plague and cholera were further benefits increasing survival of diseased subjects in a population. Thus, the reduction of exposure to deadly infectious agents might have given a chance to HIV-1 infected subjects to survive and for HIV-1 to be distributed around the world starting from Central Africa in the 1950s.

show abstract

Section: Further Possible Reasons Favoring Hiv Spread Some Decades Agomentioning

confidence: 99%

Aspects on the history of transmission and favor of distribution of viruses by iatrogenic action: perhaps an example of a paradigm of the worldwide spread of HIV

Gürtler

Eberle

2017

Med Microbiol Immunol

View full text Add to dashboard Cite

show abstract

“…There are a large number of approaches to vaccine development and generation of diagnostic tools [21][22][23]. In the case of HEV, most of the commercial and in-house serological assays are based on selected regions of immobilised ORF2 capsid protein, and some include ORF3 protein [24,25].…”

Section: Introductionmentioning

confidence: 99%

Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid

Larralde

Petrík

2017

Med Microbiol Immunol

View full text Add to dashboard Cite

Hepatitis E is an emerging zoonotic infection of increasing public health threat for the UK, especially for immunosuppressed individuals. A human recombinant vaccine has been licensed only in China and is not clear whether it protects against hepatitis E virus (HEV) genotype 3, the most prevalent in Europe. The aim of this study was to use phage display technology as a tool to identify peptides that mimic epitopes of HEV capsid (mimotopes). We identified putative linear and conformational mimotopes using sera from Scottish blood donors that have the immunological imprint of past HEV infection. Four mimotopes did not have homology with the primary sequence of HEV ORF2 capsid but competed effectively with a commercial HEV antigen for binding to anti-HEV reference serum. When the reactivity profile of each mimotope was compared with Wantai HEV-IgG ELISA, the most sensitive HEV immunoassay, mimotopes showed 95.2-100% sensitivity while the specificity ranged from 81.5 to 95.8%. PepSurf algorithm was used to map affinity-selected peptides onto the ORF2 crystal structure of HEV genotype 3, which predicted that these four mimototopes are clustered in the P domain of ORF2 capsid, near conformational epitopes of anti-HEV neutralising monoclonal antibodies. These HEV mimotopes may have potential applications in the design of structural vaccines and the development of new diagnostic tests.

show abstract

“…Hence, Purified Protein Derivative (PPD) and Interferon Release Assay (IGRA) is needed to aid in diagnosis of TB. Vaccination is often considered as an effective strategy for TB control (Doerr and Berger, 2014). The vaccination of TB that increase the immune system from infancy into adulthood would have a significant impact on global TB rates (Styblo and Meijer, 1976).…”

Section: Introductionmentioning

confidence: 99%

Strategies of Tuberculosis–HIV Vaccines Design using Immunoinformatic Approach

Fatonah

Wicaksono

Tambunan³

2019

OnLine Journal of Biological Sciences

View full text Add to dashboard Cite

Tuberculosis is amongst the highest cause death worldwide. According to WHO, an estimated of more than a million people fell ill with Tuberculosis (TB) in 2016. The resistances of the M. tuberculosis (MTb) bacteria make drugs, not that useful in battle with TB. Vaccination is a better choice to avoid the worst cases of TB. The resistance possessed by MTb bacteria with some of the drugs reported creates its challenge to reduce the high rate of TB related death. One of the concerns is the high mortality rate due to TB associated with HIV. However, there's still no effective vaccine for Tuberculosis-Human Immunodeficiency Virus (TB-HIV). Vaccines for Tuberculosis-HIV even on the way of progress to get the demanding the mutation of the bacteria and challenging scientists to get the right vaccines for this disease. Immunoinformatic is one of the approaches that can speed up the making of the vaccine.

show abstract

Vaccination against infectious diseases: What is promising?

Cited by 12 publications

References 79 publications

Aspects on the history of transmission and favor of distribution of viruses by iatrogenic action: perhaps an example of a paradigm of the worldwide spread of HIV

Aspects on the history of transmission and favor of distribution of viruses by iatrogenic action: perhaps an example of a paradigm of the worldwide spread of HIV

Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid

Strategies of Tuberculosis–HIV Vaccines Design using Immunoinformatic Approach

Contact Info

Product

Resources

About